Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Interest Expenses (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Interest Expenses data on record, last reported at $10.8 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 5.96% year-over-year to $10.8 million; the TTM value through Dec 2025 reached $44.3 million, up 9.74%, while the annual FY2025 figure was $44.3 million, 9.74% up from the prior year.
  • Interest Expenses reached $10.8 million in Q4 2025 per APLS's latest filing, down from $11.3 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $12.5 million in Q3 2024 and bottomed at $2.3 million in Q3 2021.
  • Average Interest Expenses over 5 years is $8.0 million, with a median of $7.8 million recorded in 2022.
  • Peak YoY movement for Interest Expenses: plummeted 75.98% in 2021, then soared 246.32% in 2022.
  • A 5-year view of Interest Expenses shows it stood at $3.0 million in 2021, then soared by 156.39% to $7.7 million in 2022, then dropped by 4.34% to $7.4 million in 2023, then surged by 55.82% to $11.5 million in 2024, then dropped by 5.96% to $10.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $10.8 million in Q4 2025, $11.3 million in Q3 2025, and $11.2 million in Q2 2025.